Published Paper Details:

Ulcers, particularly gastric and duodenal ulcers, have long been a significant concern in the field of gastroenterology. The understanding of their pathophysiology has evolved over the years, leading to the development of various anti-ulcer agents. This abstract provides a brief overview of the mechanisms and therapeutic prospects of anti-ulcer agents. Gastric ulcers are primarily associated with the erosion of the gastric mucosal barrier, which protects the stomach lining from the corrosive effects of gastric acid. Duodenal ulcers, on the other hand, are often linked to excessive acid production. Historically, the mainstay of ulcer treatment involved acid-suppressive medications, such as proton pump inhibitors (PPIs) and histamine receptor antagonists (H2 blockers). These drugs effectively reduced acid secretion and provided relief to patients. Recent advancements in the field have highlighted the crucial role of Helicobacter pylori infection in the development of ulcers. Eradication of this bacterium with antibiotics has become a key component of ulcer management, especially in cases where infection is confirmed. Additionally, mucosal protective agents like sucralfate have gained prominence for their ability to enhance mucosal defense mechanisms and promote ulcer healing. Prostaglandin analogs, such as misoprostol, are used to both reduce acid secretion and promote mucosal protection. In recent years, research has focused on novel therapeutic approaches, including the use of growth factors and stem cell-based therapies to accelerate ulcer healing. Furthermore, the identification of new targets within the inflammatory and oxidative stress pathways has opened up exciting avenues for drug development. In conclusion, the treatment landscape for ulcers has evolved significantly from merely suppressing gastric acid. It now encompasses a multifaceted approach that includes antimicrobial therapy, mucosal protection, and emerging regenerative strategies. These developments hold promise for improved management and enhanced outcomes for patients with ulcers. Please note that this abstract provides a general overview, and the specific details and advancements in the field of anti-ulcer agents may have evolved since my last knowledge update in September 2021